JP2001057991A - Air permeable pasting agent and its production - Google Patents
Air permeable pasting agent and its productionInfo
- Publication number
- JP2001057991A JP2001057991A JP2000161183A JP2000161183A JP2001057991A JP 2001057991 A JP2001057991 A JP 2001057991A JP 2000161183 A JP2000161183 A JP 2000161183A JP 2000161183 A JP2000161183 A JP 2000161183A JP 2001057991 A JP2001057991 A JP 2001057991A
- Authority
- JP
- Japan
- Prior art keywords
- plaster
- patch
- mesh
- pasting agent
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 239000011505 plaster Substances 0.000 claims abstract description 45
- 238000010022 rotary screen printing Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 20
- 210000002683 foot Anatomy 0.000 claims description 5
- 210000003371 toe Anatomy 0.000 claims 2
- 230000035699 permeability Effects 0.000 abstract description 16
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract description 11
- 208000010201 Exanthema Diseases 0.000 abstract description 7
- 201000005884 exanthem Diseases 0.000 abstract description 7
- 206010037844 rash Diseases 0.000 abstract description 7
- 239000004745 nonwoven fabric Substances 0.000 abstract description 6
- 239000002759 woven fabric Substances 0.000 abstract description 5
- 230000003902 lesion Effects 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 description 26
- 230000001070 adhesive effect Effects 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 10
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010061876 Obstruction Diseases 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 230000036572 transepidermal water loss Effects 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000002964 rayon Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007650 screen-printing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- 238000009941 weaving Methods 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BFUXUGOZJVHVMR-UHFFFAOYSA-N 1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1CNS(=O)(=O)C2=CC(S(=O)(=O)N)=CC=C21 BFUXUGOZJVHVMR-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- ROGIWVXWXZRRMZ-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1 ROGIWVXWXZRRMZ-UHFFFAOYSA-N 0.000 description 1
- CPHGOBGXZQKCKI-UHFFFAOYSA-N 4,5-diphenyl-1h-imidazole Chemical compound N1C=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CPHGOBGXZQKCKI-UHFFFAOYSA-N 0.000 description 1
- ZOLBALGTFCCTJF-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC=C(O)C(O)=C1.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 ZOLBALGTFCCTJF-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- RSLNRVYIRDVHLY-UHFFFAOYSA-N Tulobuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC=CC=C1Cl RSLNRVYIRDVHLY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940018435 isoproterenol sulfate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 238000007645 offset printing Methods 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229920006132 styrene block copolymer Polymers 0.000 description 1
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- 229920000247 superabsorbent polymer Polymers 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229960004846 tulobuterol hydrochloride Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は通気性の優れた貼付
剤及びその製造法に関するもので、より詳細には、適用
した際に皮膚面の被覆によるかぶれ等の皮膚障害がきわ
めて少なく、かつ、発汗等が原因で起こるむれによる粘
着力の低下がない貼付剤及びその効率的な製造法に関す
るものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a patch having excellent air permeability and a method for producing the same. More particularly, the present invention relates to a skin patch such as a rash due to coating on the skin surface when applied, and The present invention relates to a patch which does not cause a decrease in adhesive strength due to unevenness caused by sweating or the like, and an efficient production method thereof.
【0002】[0002]
【従来の技術】皮膚に適用して薬効を発揮する貼付剤は
多数提供されているが、上記の通りかぶれ等の皮膚障害
を起こすおそれのあることが一般的に欠点となってい
る。皮膚障害を起こす原因の一つに皮膚呼吸の妨害やむ
れがあるが、貼付剤と皮膚との間に溜る皮膚からの蒸散
水分や汗により皮膚のむれが起こり、角質層中の起炎物
質がその水分中に溶け出し、炎症をひき起こすことが報
告されている。2. Description of the Related Art Although a large number of patches have been provided which exert a medicinal effect when applied to the skin, as described above, there is a general drawback that skin patches such as rash may be caused. One of the causes of skin disorders is obstruction of skin respiration and unevenness.However, evaporative moisture or sweat from the skin that collects between the patch and the skin causes skin irregularity, and the inflammatory substances in the stratum corneum It has been reported to dissolve in the water and cause inflammation.
【0003】従来の通気性の低い貼付剤では、その他の
欠点として、特にむれやすい部位、例えば足の裏等へ貼
付した場合、経時的に接着力が低下し、容易に脱落する
場合があった。かといって膏体の粘着力を上げても、そ
れだけでは剥がれやめくれは解決せず、むれの抑制が必
要と考えられた。しかもこのような部位は角質層が厚
く、薬物を経皮的に吸収させるためには、多くの場合経
皮吸収促進剤が必要となるが、この経皮吸収促進剤が粘
着力をさらに低下させる要因となっていた。Another drawback of the conventional patch having low air permeability is that, when the patch is applied to a part which is particularly easily peeled, for example, the sole of a foot, the adhesive strength decreases with time and the adhesive easily falls off. . However, increasing the adhesive strength of the plaster alone did not solve the peeling or turning over, and it was considered necessary to control the unevenness. Moreover, in such a site, the stratum corneum is thick and a transdermal absorption enhancer is often required in order to absorb the drug transdermally, but this transdermal absorption enhancer further reduces the adhesive force. Was a factor.
【0004】貼付剤による皮膚呼吸の妨害やむれを緩和
する技術として、通気性を得るために機械的に支持体か
ら膏体にかけて貫通した穴あけ加工をしたものがある。
しかし、穴あけ後の貼付剤強度が低下したり、あるいは
あけられた穴の部分の支持体と膏体が無駄になることか
ら、貼付剤全体に対するその穴が占める面積の割合は多
くとも1〜5%に止まり、従ってこの方法では十分な通
気性が得られなかった。[0004] As a technique for alleviating the obstruction or irregularity of skin respiration caused by a patch, there is a technique of mechanically punching a hole from a support to a plaster to obtain air permeability.
However, since the strength of the patch after perforation is reduced or the support and the plaster at the portion of the perforated hole are wasted, the ratio of the area occupied by the hole to the entire patch is at most 1 to 5 %, And thus this method did not provide sufficient air permeability.
【0005】また、通気性支持体の片面に従来の膏体層
を施した貼付剤が通気性に優れているとされることがあ
るが、実際には膏体層自体がほとんど通気性を持たない
ため結局皮膚呼吸の妨害やむれは緩和されない。In some cases, a patch having a conventional plaster layer provided on one side of a gas-permeable support has excellent air permeability, but in practice, the plaster layer itself has almost air permeability. As a result, obstruction and unevenness of skin respiration are not alleviated.
【0006】あるいは、特開昭63−203615号や
特開平1−297069号には、皮膚呼吸や発汗による
水分を吸収させるために、膏体に高吸水性高分子を配合
した技術が開示されているが、ある程度の水分の吸収は
望めても、水分を吸収して膨潤した高吸水性高分子が皮
膚に対する貼付剤の粘着力を低下させてしまうという欠
点があった。[0006] Alternatively, JP-A-63-203615 and JP-A-1-297695 disclose a technique in which a highly water-absorbing polymer is blended into a plaster to absorb moisture due to skin respiration and perspiration. However, although a certain amount of water absorption can be expected, there is a disadvantage that the superabsorbent polymer that has absorbed water and swelled reduces the adhesive strength of the patch to the skin.
【0007】通気性支持体に多孔化された膏体層を施し
た貼付剤は通気性に優れ、皮膚呼吸の妨害やむれの緩和
に優れた効果が期待できる。従来から様々な貼付剤及び
その製造方法が報告されている。例えば、特公昭51−
10854号には、膏体の乾燥工程において膏体の収縮
により割れ目を生じさせたものが記載されているが、乾
燥効率が悪い、均一な気孔が得られない等の問題点があ
った。[0007] A patch in which a porous layer is applied to a breathable support is excellent in breathability, and can be expected to have an excellent effect in preventing skin respiration and alleviating unevenness. Conventionally, various patches and methods for producing the same have been reported. For example,
Japanese Patent No. 10854 describes a method in which a crack is generated by shrinkage of the paste in the step of drying the paste, but has problems such as poor drying efficiency and uniform pores cannot be obtained.
【0008】また、特公昭62−14197号には膏体
に発泡剤を添加し膏体の発泡部にて通気性を出すものが
記載されているが、温度による発泡状態の変化、発泡に
よる粘着力低下の恐れがあった。Japanese Patent Publication No. Sho 62-14197 discloses a method in which a foaming agent is added to a plaster to provide air permeability at a foaming portion of the plaster. There was a risk of weakness.
【0009】特公昭51−33811号には、膏体に気
泡あるいは液泡を分散させ、これらの気泡あるいは液泡
で通気性を出すものが記載されているが、気泡あるいは
液泡の分散された膏体の安定性に問題があった。Japanese Patent Publication No. 51-33811 describes a method in which air bubbles or liquid bubbles are dispersed in a plaster, and the air bubbles are formed by the air bubbles or the liquid bubbles. There was a problem with stability.
【0010】特開昭56−2909号には、グラビアロ
ール法、オフセット印刷法、シルクスクリーン印刷法等
の印刷方式により膏体を多数の列状にあるいは網目状に
塗工する技術が開示されているが、グラビアロール法な
どのロール法による印刷塗工では、ロールによる加圧の
ために印刷される膏体が潰されて、前記膏体間の通気性
支持体表面が膏体で塞がるために良好な通気性が得られ
ないという問題点があった。また、シルクスクリーン印
刷法では連続生産ができず、コスト高になるという問題
点があった。Japanese Patent Application Laid-Open No. 56-2909 discloses a technique in which plasters are applied in a number of rows or in a mesh by a printing method such as a gravure roll method, an offset printing method, and a silk screen printing method. However, in printing coating by a roll method such as a gravure roll method, the paste to be printed is crushed due to pressurization by the roll, and the air-permeable support surface between the pastes is closed by the paste. There was a problem that good air permeability could not be obtained. In addition, the silk screen printing method has a problem in that continuous production cannot be performed and the cost increases.
【0011】特開平11−33103号には、通気性基
材の一面に、密度0.93g/cm3以下の低密度ポリ
エチレンが厚さ3〜10μmで積層されている積層基材
のポリエチレン積層面に、固形分10〜70重量%の粘
着剤の有機溶剤溶液を乾燥後の塗布量が5〜100g/
m2となるように塗布し、130〜200℃に加熱し、
乾燥させると共に上記低密度ポリエチレン層に無数の微
細な孔を形成させることを特徴とする通気性粘着テープ
の製造方法が記載されているが、粘着剤層には孔がない
ので、かぶれ等の皮膚障害を緩和するのに十分な通気性
は得られない。また、当該公報にはさらに、レーヨン繊
維及び/又はセルロース繊維を10〜100重量%含有
し、通気性基材に、該通気性基材重量100重量部に対
して0.5〜50重量部含水させた後、リバースコータ
ーを用いて固形分10〜70重量%の粘着剤の有機溶剤
溶液を乾燥後の塗布量が5〜100g/m2となるよう
に塗布し、130〜200℃に加熱し、乾燥させると共
に該粘着剤層に無数の微細な孔を形成させることを特徴
とする通気性粘着テープ製造方法が記載されているが、
形成される微細な孔が通気性基材の表面状態、乾燥温
度、粘着剤の粘性により左右されるので全面に均一な孔
を得ることは困難であった。また、無数の孔が形成され
た場合、その孔の占める面積の割合は必ずしも一定しな
いため粘着力等の物性がばらつく等の欠点があった。Japanese Patent Application Laid-Open No. 11-33103 discloses a polyethylene laminated surface of a laminated base material in which low-density polyethylene having a density of 0.93 g / cm 3 or less is laminated on one surface of a gas permeable base material at a thickness of 3 to 10 μm. The coating amount after drying the organic solvent solution of the pressure-sensitive adhesive having a solid content of 10 to 70% by weight is 5 to 100 g /
m 2 and heated to 130-200 ° C.
A method for producing a breathable pressure-sensitive adhesive tape characterized by drying and forming a myriad of fine holes in the low-density polyethylene layer is described, but since the pressure-sensitive adhesive layer has no holes, skin such as rash Insufficient air permeability to mitigate the obstacle is not obtained. The publication further contains 10 to 100% by weight of rayon fiber and / or cellulose fiber, and the permeable base material contains 0.5 to 50 parts by weight of water per 100 parts by weight of the permeable base material. After that, an organic solvent solution of the adhesive having a solid content of 10 to 70% by weight was applied using a reverse coater so that the applied amount after drying was 5 to 100 g / m 2, and heated to 130 to 200 ° C. A method for producing a breathable pressure-sensitive adhesive tape, characterized by drying and forming an infinite number of fine holes in the pressure-sensitive adhesive layer,
It was difficult to obtain uniform pores over the entire surface because the fine pores formed depend on the surface condition of the air-permeable substrate, the drying temperature, and the viscosity of the adhesive. Further, when an infinite number of holes are formed, the ratio of the area occupied by the holes is not always constant, so that there is a disadvantage that physical properties such as adhesive strength vary.
【0012】上述のように、従来の通気性貼付剤及びそ
の製造方法には、貼付剤全面に均一な気孔が得られな
い、製造条件のコントロールが至難である、貼付剤とし
て必要な粘着性に欠ける、気孔が短時間で消失する、充
分な通気性が得られない、必要な膏体量(薬効成分量)
が塗布できない、連続生産ができない、工程が複雑であ
るなど多くの問題点が残されている。As described above, the conventional air-permeable patch and the method for producing the same do not provide uniform pores over the entire surface of the patch, make it difficult to control the production conditions, and reduce the adhesiveness required for the patch. Chipping, pores disappear in a short time, sufficient air permeability cannot be obtained, required amount of plaster (amount of medicinal ingredient)
However, there are still many problems such as inability to apply, continuous production, and complicated processes.
【0013】[0013]
【発明が解決しようとする課題】本発明は上記従来技術
の持つ欠点を解決するため、「貼付剤の全面に均一な気
孔の存在」、「貼付剤としての充分な粘着性」、「必要
な薬効成分量を確保できる膏体量」及び「膏体塗工量の
均一性」を併せ持った貼付剤を提供し、従来の貼付剤に
あった皮膚呼吸の妨害やむれによるかぶれ等の皮膚障害
を緩和することが本発明の課題であり目的である。SUMMARY OF THE INVENTION In order to solve the above-mentioned drawbacks of the prior art, the present invention is directed to "existence of uniform pores over the entire surface of the patch", "sufficient adhesiveness as a patch", We provide patches that combine the amount of plaster that can secure the amount of medicinal ingredients and the uniformity of the amount of plaster applied to prevent skin disorders such as obstruction of skin respiration and rash due to irregularities, which were present in conventional patches. Relaxation is an object and object of the present invention.
【0014】[0014]
【課題を解決するための手段】そこで、本発明者らは、
粘着技術及び多孔化技術に関し鋭意研究の結果、織布又
は不織布等の通気性支持体の片面に、膏体をロータリス
クリーン印刷方式で、網目の大きさが10〜60メッシ
ュの大きさになるように、網目状又は網目で構成される
パターン状に間隙を有して施すことで通気性の優れた貼
付剤を得るに至り、皮膚呼吸の妨害やむれが緩和された
通気性貼付剤を完成した。Means for Solving the Problems Accordingly, the present inventors have:
As a result of earnest research on the adhesive technology and the porous technology, on one side of a breathable support such as a woven fabric or a nonwoven fabric, the paste is formed by rotary screen printing so that the mesh size becomes 10 to 60 mesh. In addition, a patch having excellent breathability was obtained by applying a gap having a mesh shape or a pattern composed of meshes, and a breathable patch was obtained in which interference with skin respiration and relief were reduced. .
【0015】また、その結果本発明の通気性貼付剤が、
発汗の多い場所あるいはむれやすい場所に長時間粘着が
可能となることも見出した。これは、特に足の裏への貼
付剤の適用(例:足白癬の治療等)を考えた場合、非常
に好都合な特性と考えられる。As a result, the breathable patch of the present invention is
It has also been found that it is possible to stick for a long period of time in places where sweating is likely or where it is likely to be disturbed. This is considered to be a very advantageous property, especially when considering the application of the patch to the sole of the foot (eg treatment of tinea pedis, etc.).
【0016】本発明に使用する支持体は、通気性を有す
るものなら特に限定されず、織布、不織布などが使用で
きる。例えば、織布として綿、スフ、ナイロン、レーヨ
ン、ポリエステル、ポリプロピレンなどの繊維の織布が
用いられ、織り方、密度、繊維デニールなどは特に限定
されない。不織布としてレーヨン、セルロース、ナイロ
ン、ポリプロピレン、ポリエステルなどの繊維の単独又
はこれらの混抄品が用いられ、織り方、密度、繊維デニ
ールなどは特に限定されない。The support used in the present invention is not particularly limited as long as it has air permeability, and a woven fabric, a nonwoven fabric and the like can be used. For example, a woven fabric of fibers such as cotton, woolen, nylon, rayon, polyester, and polypropylene is used as the woven fabric, and the weaving method, density, fiber denier, and the like are not particularly limited. As the nonwoven fabric, a single fiber of rayon, cellulose, nylon, polypropylene, polyester or the like or a mixture thereof is used, and the weaving method, density, fiber denier and the like are not particularly limited.
【0017】本発明の通気性貼付剤に使用する膏体の基
剤となる粘着剤は、油性粘着剤の中から適宜選択され
る。粘着剤の成分としては、スチレン−イソプレン−ス
チレンブロック共重合体、スチレン−ブタジエン−スチ
レンブロック共重合体、ポリアクリル酸エステル共重合
体、天然ゴム、各種合成ゴム等が挙げられ、粘着力など
粘着物性の必要に応じてテルペン系樹脂、脂肪族系合成
樹脂、ロジン系樹脂、ロジンエステル系樹脂などの粘着
付与剤や、流動パラフィン、ナフテン系オイル、ポリブ
テン、ポリイソブチレンなどの軟化剤や、酸化チタン、
酸化亜鉛などの充てん剤や、老化防止剤を配合してなる
ものが例示される。The pressure-sensitive adhesive serving as the base of the plaster used in the breathable patch of the present invention is appropriately selected from oil-based pressure-sensitive adhesives. Examples of the component of the adhesive include styrene-isoprene-styrene block copolymer, styrene-butadiene-styrene block copolymer, polyacrylate copolymer, natural rubber, various synthetic rubbers, and the like. Tackifier such as terpene resin, aliphatic synthetic resin, rosin resin, rosin ester resin, softener such as liquid paraffin, naphthene oil, polybutene, polyisobutylene, and titanium oxide as needed ,
Examples thereof include fillers such as zinc oxide and those obtained by blending an antioxidant.
【0018】また、本発明の通気性貼付剤に使用するこ
とのできる薬効成分の代表例として下記のものが挙げら
れる。 コルチコステロイド類:例えばハイドロコルチゾン、プ
レドニゾロン、ベクロメタゾンプロピオネート、フルメ
タゾンなど、 鎮痛消炎剤:例えばアセトアミノフェノン、メフェナム
酸、フルフェナック酸、ジクロフェナックナトリウム、
サリチル酸、サリチル酸モノグリコール、1−メントー
ル、カンファーなど、 催眠鎮静剤:例えばフエノバルビタール、アモバルビタ
ール、トリアゾラムなど、 精神安定剤:例えばフルフエナジン、テオリタジン、ジ
アゼパム、クロルプロマジンなど、 抗高血圧剤:例えばクロニジン、ピンドロール、プロプ
ラノロール、ブプラノロールなど、 降圧利尿剤:例えばハイドロサイアザイド、ベンドロフ
ルナサイアザイドなど、 抗生物質:例えばペニシリン、テトラサイクリン、オキ
シテトラサイクリン、塩酸フラジオマイシンなど、 麻酔剤:例えばリドカイン、塩酸ジブカイン、ベンゾカ
イン、アミノ安息香酸エチルなど、 抗菌性物質:例えば塩化ベンザルコニウム、ニトロフラ
ゾン、アセトスルファミン、クロトリマゾール、トルナ
フテート、ビホナゾール、テルビナフィンなど、 ビタミン剤:例えばビタミンA、エルゴカルシフェロー
ル、リボフラビン酪酸エステルなど、 抗てんかん剤:例えばニトラゼパム、メプロバメート、
クロナゼパムなど、 冠血管拡張剤:例えばニトログリセリン、イソソルビド
ジナイトレート、ペンタエリスリトールテトラナイトレ
ートなど、 抗ヒスタミン剤:例えば塩酸ジフェンヒドラミン、クロ
ルフェニラミン、ジフェニルイミダゾールなど、 鎮咳剤:例えば硫酸サルブタモール、イソプロテレノー
ル、塩酸ツロブテロール、エフェドリンなど、 性ホルモン:例えばプロゲステロン、エストラジオール
など、 制吐剤:例えばスコポラミン、クレボプライド、5−フ
ルオロウラシル、メルカプトプリンなどが挙げられ、こ
れらの薬物は必要に応じて2種類以上併用できる。The following are typical examples of medicinal ingredients that can be used in the breathable patch of the present invention. Corticosteroids: for example, hydrocortisone, prednisolone, beclomethasone propionate, flumethasone, etc. Analgesic and anti-inflammatory agents: for example, acetaminophenone, mefenamic acid, flufenac acid, diclofenac sodium,
Salicylic acid, monoglycol salicylate, 1-menthol, camphor, etc. Hypnotic sedatives: for example, phenobarbital, amobarbital, triazolam, etc. Mental stabilizers: for example, fluphenazine, theorytazine, diazepam, chlorpromazine, etc. Antihypertensive agents: for example, clonidine, pindolol , Propranolol, bupranolol, etc. Antihypertensive diuretics: for example, hydrothiazide, bendroflunathiazide, etc. Antibiotics: for example, penicillin, tetracycline, oxytetracycline, fradiomycin hydrochloride, etc. Anesthetics: for example, lidocaine, dibucaine hydrochloride, benzocaine, aminobenzoic acid Antibacterial substances such as ethyl: for example benzalkonium chloride, nitrofurazone, acetosulfamine, clotrimazole, tolnaphte Vitamins: for example, vitamin A, ergocalciferol, riboflavin butyrate, etc. Antiepileptic agents: for example, nitrazepam, meprobamate,
Clonazepam, etc. Coronary vasodilators: nitroglycerin, isosorbide dinitrate, pentaerythritol tetranitrate, etc. Antihistamines: diphenhydramine hydrochloride, chlorpheniramine, diphenylimidazole, etc. Antitussives: salbutamol sulfate, isoproterenol sulfate, tulobuterol hydrochloride , Ephedrine, etc. Sex hormones: for example, progesterone, estradiol, etc. Antiemetic agents: for example, scopolamine, crevopride, 5-fluorouracil, mercaptopurine, etc. These drugs can be used in combination of two or more as necessary.
【0019】また、本発明の通気性貼付剤には薬物の経
皮吸収性を向上させるために、エチレングリコール、ジ
エチレングリコールなどのグリコール類、オリーブ油、
ヒマシ油、ハッカ油などの油脂類などを吸収助剤として
配合してもよい。The breathable patch of the present invention contains glycols such as ethylene glycol and diethylene glycol, olive oil,
Oils and fats such as castor oil and peppermint oil may be blended as an absorption aid.
【0020】本発明においては、膏体をロータリスクリ
ーン印刷方式を用いて施すことが特徴の一つであり、こ
れにより支持体及び膏体を無駄にすることなく、膏体を
通気性支持体に、網目状又は網目で構成されるパターン
状に間隙を有して連続的に施すことができる。ロータリ
シリンダにメッシュ加工される網目の大きさ及びパター
ンの形状で、膏体の網目の大きさ及び施される膏体量が
決定される。従って、必要に応じた大きさの網目及びパ
ターンの形状をロータリシリンダにメッシュ加工するこ
とで、貼付剤全面に均一な気孔の存在を確保でき、必要
量の膏体を均一に施すことができる。また、必要量の膏
体が均一に施されることで、貼付剤全面に必要量の薬効
成分が均一に確保できるとともに、貼付剤として充分な
粘着性も得られる。この時、網目の大きさを10〜60
メッシュとすることで、均一な塗工の場合、1平方メー
トル当たりの膏体塗工量を、一般の貼付剤(テープ剤)
に必要とされる膏体量200〜20gにすることができ
る。図1に、支持体に網目状に間隙を有して連続的に施
した膏体の状態をあらわした概略図を示す。One of the features of the present invention is that the paste is applied by using a rotary screen printing method, so that the paste and the paste can be applied to the air-permeable support without wasting the support and the paste. It can be applied continuously with a gap in the form of a mesh or a pattern composed of meshes. The size of the mesh of the plaster and the amount of the plaster to be applied are determined by the size of the mesh and the shape of the pattern to be meshed on the rotary cylinder. Therefore, by meshing a mesh and a pattern having a size as required on the rotary cylinder, uniform pores can be ensured on the entire surface of the patch, and a required amount of plaster can be uniformly applied. In addition, since the required amount of the plaster is uniformly applied, the required amount of the medicinal component can be uniformly provided on the entire surface of the patch, and sufficient adhesiveness as the patch can be obtained. At this time, the size of the mesh is 10 to 60
In the case of uniform coating by using a mesh, the amount of plaster applied per square meter can be reduced by a general patch (tape).
The amount of plaster required for the above can be 200 to 20 g. FIG. 1 is a schematic diagram showing a state of a plaster continuously applied with a mesh-like gap on a support.
【0021】[0021]
【作用】本発明の貼付剤は優れた通気性を持ち、貼付に
よる皮膚呼吸の妨害やむれが著しく緩和される。その結
果、特に慢性疾患のように長期間の使用が必要な場合、
かぶれ等の皮膚障害の発生のため従来の貼付剤では困難
であった連続(反復)貼付を安全に行うことを可能とし
た。また、従来では容易に剥離してしまっていたむれや
すい場所、例えば足の裏や指等への貼付においても、長
時間にわたって安定に貼付させることを可能とした。さ
らに、ロータリスクリーン印刷方式を採用することよ
り、支持体及び膏体を無駄なく使用することが可能であ
る。以下に実施例を挙げ本発明をさらに具体的に説明す
る。The patch of the present invention has excellent air permeability and remarkably relieves skin respiration and peeling caused by the patch. As a result, long-term use is necessary, especially for chronic diseases,
Continuous (repeated) patching, which was difficult with conventional patches due to the occurrence of skin disorders such as rashes, has been made possible safely. In addition, it has been possible to stably adhere to a place that is easily peeled off in the past, such as the sole of the foot or a finger, for a long time. Further, by employing the rotary screen printing method, the support and the plaster can be used without waste. Hereinafter, the present invention will be described more specifically with reference to examples.
【0022】[0022]
【実施例】(実施例1)粘着剤の原料としてスチレン−
イソプレン−スチレンブロック共重合体100重量部、
脂環族飽和炭化水素樹脂120重量部、流動パラフィン
40重量部を投入し、タンク温度を160℃に加熱し攪
拌した。原料を溶融・混合し粘着剤を得た。粘着剤を1
00℃に冷却後、サリチル酸グリコール20重量部、メ
ントール20重量部を加え充分攪拌して膏体を得た。得
られた膏体を、網目の大きさを16メッシュの四角形状
に加工したロータリシリンダが装着されたロータリスク
リーン印刷方式の塗工機を用い、通気性不織布の片面に
網目状に施し、その粘着面に剥離紙を貼り合わせ貼付剤
とした。得られた貼付剤は、1平方メートル当たりの膏
体量が120gであった。なお、膏体の皮膚への理論上
の接触面積は、全面塗工の場合の約50%となった。網
目状に施された膏体の配置を示した模式図を図2に示
す。EXAMPLES (Example 1) Styrene was used as a raw material for an adhesive.
100 parts by weight of isoprene-styrene block copolymer,
120 parts by weight of an alicyclic saturated hydrocarbon resin and 40 parts by weight of liquid paraffin were charged, and the tank was heated to 160 ° C. and stirred. The raw materials were melted and mixed to obtain an adhesive. 1 adhesive
After cooling to 00 ° C., 20 parts by weight of glycol salicylate and 20 parts by weight of menthol were added and sufficiently stirred to obtain a plaster. Using a rotary screen printing type coating machine equipped with a rotary cylinder having a mesh size of 16 mesh square, the obtained plaster was applied to one side of a breathable nonwoven fabric in a mesh form, and the adhesive was applied. A release paper was stuck on the surface to give a patch. The obtained patch had a plaster weight of 120 g per square meter. In addition, the theoretical contact area of the plaster to the skin was about 50% of that in the case of the whole surface application. FIG. 2 is a schematic diagram showing the arrangement of the plasters applied in a mesh form.
【0023】(実施例2)ロータリシリンダの編目の大
きさが10メッシュであること以外は実施例1と同様に
して、本発明の貼付剤を得た。得られた貼付剤は、1平
方メートル当たりの膏体量が200gであった。Example 2 A patch of the present invention was obtained in the same manner as in Example 1 except that the size of the stitch of the rotary cylinder was 10 mesh. The obtained patch had a plaster weight per square meter of 200 g.
【0024】(実施例3)ロータリシリンダの編目の大
きさが60メッシュであること以外は実施例1と同様に
して、本発明の貼付剤を得た。得られた貼付剤は、1平
方メートル当たりの膏体量が20gであった。Example 3 A patch of the present invention was obtained in the same manner as in Example 1 except that the size of the stitch of the rotary cylinder was 60 mesh. The resulting patch had a plaster weight per square meter of 20 g.
【0025】(実施例4)ロータリシリンダの編目が円
形であること以外は実施例1と同様にして、本発明の貼
付剤を得た。網目状に施された膏体の配置を示した模式
図を図3に示す。Example 4 A patch of the present invention was obtained in the same manner as in Example 1 except that the stitches of the rotary cylinder were circular. FIG. 3 is a schematic view showing the arrangement of the plasters formed in a mesh.
【0026】(実施例5)ロータリシリンダの編目が六
角形であること以外は実施例1と同様にして、本発明の
貼付剤を得た。網目状に施された膏体の配置を示した模
式図を図4に示す。Example 5 A patch of the present invention was obtained in the same manner as in Example 1 except that the stitches of the rotary cylinder were hexagonal. FIG. 4 is a schematic diagram showing the arrangement of the plasters applied in a mesh form.
【0027】(実施例6)編目が五角形であり、それら
の集合パターンが筋状を形成するように加工したロータ
リシリンダを使用したこと以外は実施例1と同様にし
て、本発明の貼付剤を得た。網目状に施された膏体の配
置を示した模式図を図5に示す。(Example 6) The patch of the present invention was prepared in the same manner as in Example 1 except that the stitches were pentagonal, and a rotary cylinder processed so that the aggregate pattern formed streaks was used. Obtained. FIG. 5 is a schematic diagram showing the arrangement of the plasters applied in a mesh.
【0028】(比較例1)実施例で得られた膏体を、ド
クターナイフコーターを用い、実施例と同じ不織布の片
面に、1平方メートル当たりの膏体量が120gになる
ように全面に施した。施された粘着面に剥離紙を貼り合
わせ貼付剤とした。(Comparative Example 1) The plaster obtained in the example was applied to one surface of the same nonwoven fabric as in the example using a doctor knife coater so that the amount of plaster per square meter was 120 g. . A release paper was adhered to the applied adhesive surface to obtain a patch.
【0029】次に本発明の貼付剤を使用した場合の経皮
水分蒸散量及び対皮膚粘着力の試験結果を示し、本発明
の貼付剤の優れた通気性及び粘着性を明らかにする。Next, the results of tests of the amount of transepidermal water evaporation and the adhesion to skin when the patch of the present invention is used are shown, and the excellent air permeability and adhesiveness of the patch of the present invention are clarified.
【0030】(試験例1)本試験は経皮水分蒸散量の測
定である。実施例1及び比較例1の貼付剤を前腕内側に
30分貼付し、貼付剤表面からの経皮水分蒸散量を測定
装置(引張り試験機)で測定した。コントロールとして
未貼付部からの経皮水分蒸散量を測定した。その結果を
図6に示す。図6から明らかな通り、膏体を網目状に施
した実施例1は、全面に施した比較例1と比較し、コン
トロール(未貼付部位)に近い経皮水分蒸散量を示し、
通気性がきわめて優れていることが確認された。(Test Example 1) This test is a measurement of transepidermal water loss. The patches of Example 1 and Comparative Example 1 were stuck on the inner side of the forearm for 30 minutes, and the amount of transdermal water evaporation from the patch surface was measured with a measuring device (tensile tester). As a control, the transepidermal water loss from the unapplied part was measured. FIG. 6 shows the result. As is clear from FIG. 6, Example 1 in which the plaster was applied in a mesh form showed a transepidermal water loss close to that of the control (unapplied portion), as compared with Comparative Example 1 in which the plaster was applied to the entire surface.
It was confirmed that the air permeability was extremely excellent.
【0031】(試験例2)本試験は対皮膚粘着力の測定
である。実施例1及び比較例1の貼付剤をヒトの背中に
30分貼付し、その貼付剤を剥離する時の抵抗力を測定
装置(引張り試験機)で測定した(n=5)。その結果
を図7に示す。実施例1は比較例1の粘着面積の約50
%に過ぎないにもかかわらず、それと同等な対皮膚粘着
力を示した。(Test Example 2) This test is a measurement of adhesion to skin. The patches of Example 1 and Comparative Example 1 were adhered to the back of a human for 30 minutes, and the resistance when the patches were peeled was measured with a measuring device (tensile testing machine) (n = 5). FIG. 7 shows the result. In Example 1, the adhesive area of Comparative Example 1 was about 50.
Despite being only%, it exhibited comparable skin adhesion to skin.
【0032】(試験例3)本試験は対皮膚粘着力の経時
変化の測定である。実施例1及び比較例1の貼付剤をヒ
トの足の裏に貼付し、各時間経過後にその貼付剤を剥離
する時の抵抗力を測定装置(引張り試験機)で測定した
(n=5)。その結果を図8に示す。比較例1の皮膚粘
着力は経時的に低下し、貼付24時間後には貼付部位よ
り剥がれていた。一方、実施例1は経時的な粘着力の低
下は認められず、24時間後においても十分な皮膚粘着
力を示した。(Test Example 3) This test is a measurement of the change over time in the adhesive strength to skin. The adhesive patches of Example 1 and Comparative Example 1 were applied to the soles of human feet, and after each time, the adhesive force when peeling the adhesive patches was measured with a measuring device (tensile tester) (n = 5). . FIG. 8 shows the result. The skin adhesive strength of Comparative Example 1 decreased with time, and was peeled off from the application site 24 hours after application. On the other hand, in Example 1, no decrease in the adhesive force over time was observed, and sufficient adhesive force was exhibited even after 24 hours.
【0033】[0033]
【発明の効果】本発明の通気性貼付剤は、通気性支持体
に施された膏体が網目状に間隔をもって存在するため、
きわめて通気性に優れる。そのため、皮膚呼吸の妨害や
むれを緩和し、皮膚のむれが少なく、かぶれ等の皮膚障
害がきわめて少ない。従って、特に長期間繰り返し貼付
することが必要な慢性疾患患者等への使用に対しては非
常に好ましい貼付剤である。さらに、本発明の通気性貼
付剤は、むれやすい場所、例えば足の裏や指等への貼付
においても長時間にわたって安定に貼付することが可能
である。また、本発明の通気性貼付剤はロータリスクリ
ーン印刷方式によるため、膏薬や支持体原料のロスがな
く、通気性を発現させるための特別な工程も必要ないた
め、製造コストにおいても非常に優れている。EFFECT OF THE INVENTION The air-permeable patch of the present invention is characterized in that the plasters applied to the air-permeable support are present in a mesh pattern at intervals.
Extremely breathable. Therefore, obstruction and unevenness of skin respiration are alleviated, skin unevenness is reduced, and skin disorders such as rash are extremely reduced. Therefore, it is a very preferable patch particularly for use in chronic disease patients and the like that need to be repeatedly patched for a long time. Further, the breathable patch of the present invention can be stably stuck for a long time even in a place where it is easily peeled, for example, a sole or a finger. Further, since the air-permeable patch of the present invention is based on the rotary screen printing method, there is no loss of plaster or raw material of the support, and there is no need for a special step for expressing air permeability, so that the production cost is extremely excellent. I have.
【図1】本発明の通気性貼付剤の、膏体が支持体上に網
目状に施された様子を示す概略図である。FIG. 1 is a schematic view showing a state in which a plaster of a breathable patch of the present invention is applied in a mesh on a support.
【図2】実施例1の網目状に施された膏体の配置を示し
た模式図である。FIG. 2 is a schematic diagram showing the arrangement of the plasters applied in a mesh form in Example 1.
【図3】実施例4の網目状に施された膏体の配置を示し
た模式図である。FIG. 3 is a schematic diagram showing an arrangement of a plaster applied in a mesh form in Example 4.
【図4】実施例5の網目状に施された膏体の配置を示し
た模式図である。FIG. 4 is a schematic view showing an arrangement of a plaster body applied in a mesh form in Example 5.
【図5】実施例6の網目状に施された膏体の配置を示し
た模式図である。FIG. 5 is a schematic view showing an arrangement of a plaster applied in a mesh form in Example 6.
【図6】実施例1及び比較例1の経皮水分蒸散量を示し
たグラフである。FIG. 6 is a graph showing transepidermal water loss in Example 1 and Comparative Example 1.
【図7】実施例1及び比較例1の粘着力を示したグラフ
である。FIG. 7 is a graph showing the adhesive strength of Example 1 and Comparative Example 1.
【図8】実施例1及び比較例1の粘着力の経時変化を示
したグラフである。FIG. 8 is a graph showing the change over time in the adhesive strength of Example 1 and Comparative Example 1.
1 膏体 2 支持体 3 間隙 1 plaster 2 support 3 gap
Claims (7)
目状に存在することを特徴とする通気性貼付剤。1. A breathable patch, wherein the plaster applied to one surface of the breathable support is present in a mesh form.
成されていることを特徴とする請求項1記載の通気性貼
付剤。2. The breathable patch according to claim 1, wherein the plaster is formed in a pattern consisting of a mesh.
あることを特徴とする請求項1または請求項2記載の通
気性貼付剤。3. The breathable patch according to claim 1, wherein the mesh of the plaster has a circular to polygonal shape.
されていることを特徴とする請求項1〜請求項3のいず
れかに記載の通気性貼付剤。4. The air-permeable patch according to claim 1, wherein a pattern of the formed mesh is formed in a streak shape.
ュであることを特徴とする請求項1〜請求項4のいずれ
かに記載の通気性貼付剤。5. The breathable patch according to claim 1, wherein the mesh size of the plaster is 10 to 60 mesh.
とを特徴とする請求項1〜請求項5記載の通気性貼付
剤。6. The breathable patch according to claim 1, which is used for the sole of the foot or between the toes or toes.
気性支持体の片面に膏体を網目状又は網目で構成される
パターン状に施すことを特徴とする通気性貼付剤の製造
方法。7. A method for producing a breathable patch, comprising applying a plaster on one surface of a breathable support in a mesh or a pattern constituted by a mesh by a rotary screen printing method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000161183A JP2001057991A (en) | 1999-06-16 | 2000-04-21 | Air permeable pasting agent and its production |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11-208088 | 1999-06-16 | ||
JP20808899 | 1999-06-16 | ||
JP2000161183A JP2001057991A (en) | 1999-06-16 | 2000-04-21 | Air permeable pasting agent and its production |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001057991A true JP2001057991A (en) | 2001-03-06 |
Family
ID=26516638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000161183A Pending JP2001057991A (en) | 1999-06-16 | 2000-04-21 | Air permeable pasting agent and its production |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2001057991A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008272340A (en) * | 2007-05-07 | 2008-11-13 | Yasushi Ishida | Tape for taping |
WO2010048064A2 (en) * | 2008-10-20 | 2010-04-29 | The Brigham And Women's Hospital, Inc. | Drug delivery system and its use in the treatment of postherpetic neuralgia |
-
2000
- 2000-04-21 JP JP2000161183A patent/JP2001057991A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008272340A (en) * | 2007-05-07 | 2008-11-13 | Yasushi Ishida | Tape for taping |
WO2008139816A1 (en) * | 2007-05-07 | 2008-11-20 | Yasushi Ishida | Taping tape |
WO2010048064A2 (en) * | 2008-10-20 | 2010-04-29 | The Brigham And Women's Hospital, Inc. | Drug delivery system and its use in the treatment of postherpetic neuralgia |
WO2010048064A3 (en) * | 2008-10-20 | 2010-07-08 | The Brigham And Women's Hospital, Inc. | Drug delivery system and its use in the treatment of postherpetic neuralgia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6465004B1 (en) | Solubility enhancement of drugs in transdermal drug delivery systems and methods of use | |
EP0464573B1 (en) | Plaster high in softening substances | |
AT395815B (en) | THERAPEUTIC DELIVERY SYSTEM FOR THE ADMINISTRATION OF AN ACTIVE SUBSTANCE THROUGH THE SKIN | |
EP1716850B1 (en) | Transdermal plaster | |
EP0914820B1 (en) | Plasters containing active agents having a partially applied adhesive composition | |
EP1121941B1 (en) | Sorbefacients and preparations for percutaneous absorption containing the same | |
EP0787488A1 (en) | Percutaneously absorbable patch | |
DE10212864B4 (en) | Polymer matrices comprising a mixing system for solubilization of pharmaceutical agents, processes for their preparation and their use | |
WO2001052823A2 (en) | Compositions to effect the release profile in the transdermal administration of drugs | |
JP2004174202A (en) | Plaster | |
JP2006206471A (en) | Tape preparation | |
KR20020011964A (en) | Sheet-form adhesive preparation | |
EP1085914B1 (en) | Plaster containing an active agent | |
EP1053030B1 (en) | Supporting material for medicinal purposes | |
US20180235903A1 (en) | Fentanyl Transdermal Delivery System | |
WO2006018340A1 (en) | Active agent-containing plaster strip for treating joint diseases | |
WO1999036061A1 (en) | Plasticizer and patch containing the plasticizer | |
EP1052979A1 (en) | Device for releasing substances | |
US20190015352A1 (en) | Applicators & Patches for Dermal & Transdermal Treatment Material & Drug Delivery, Methods of Making Them, & Methods of Use | |
JP2001057991A (en) | Air permeable pasting agent and its production | |
JP3233732B2 (en) | Method for producing breathable adhesive tape | |
JP4167750B2 (en) | Transdermal absorption base and percutaneous absorption preparation containing the base | |
JPH06145050A (en) | Production of patch | |
JPH09268123A (en) | Cataplasm for local anesthesia | |
WO1998046267A1 (en) | Base composition for percutaneous absorption and percutaneously absorbable preparation containing the base composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040401 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040903 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051011 |